Ivan Bergstein
Chief Executive Officer at STEMLINE THERAPEUTICS, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kenneth Hoberman | M | 59 |
Lirum Therapeutics, Inc.
 Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 11 years |
| David Gionco | M | 63 | 10 years | |
| Mark Sard | M | 59 |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 5 years |
| Daniel Hume | M | 57 |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 5 years |
| Jeffrey Levitt | M | - | 6 years | |
| Matt Hoberman | M | - |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 2 years |
| Nassir Habboubi | M | - | 3 years | |
| Peter McDonald | M | - |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Shay Shemesh | M | 41 | 5 years | |
| J. Buchi | M | 69 | 4 years | |
| Eric Dobmeier | M | 55 | 6 years | |
| Stephen Hall | M | 73 | - | |
| Kenneth Zuerblis | M | 64 | 8 years | |
| Christopher L. Brooks | M | - | - | |
| Robert Francomano | M | 58 | 5 years | |
| Jonathan Schwartz | M | 60 | 2 years | |
| Enrique Poradosu | M | 58 | 4 years | |
| Darren Cline | M | 59 | - | |
| Mark Jacobson | M | 40 | 5 years | |
| John Cavan | M | 65 | 6 years | |
| Ronald Bentsur | M | 58 | 11 years | |
| Thomas P. Cirrito | M | 51 | - | |
| Alan Forman | M | 58 | 5 years | |
| Eric Rowinsky | M | 67 | 5 years | |
| Trishna Goswami | M | 46 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 25 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ivan Bergstein
- Personal Network
